The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Executes the first project for developing and manufacturing a novel anticancer mAb
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
To accelerate the development of next-generation radioconjugates to treat cancer
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Subscribe To Our Newsletter & Stay Updated
